Compare PKOH & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | OBIO |
|---|---|---|
| Founded | 1907 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.5M | 246.2M |
| IPO Year | 1994 | 2020 |
| Metric | PKOH | OBIO |
|---|---|---|
| Price | $24.34 | $4.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $14.25 |
| AVG Volume (30 Days) | 26.7K | ★ 219.9K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $1,599,100,000.00 | $33,482,000.00 |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | $3.42 | $5.20 |
| P/E Ratio | $14.31 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $15.52 | $2.20 |
| 52 Week High | $29.50 | $5.42 |
| Indicator | PKOH | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 49.57 |
| Support Level | $23.71 | $4.02 |
| Resistance Level | $29.00 | $4.88 |
| Average True Range (ATR) | 1.12 | 0.28 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 58.54 | 44.59 |
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.